About
Fascin Inhibitors
Areas of Focus
Categories
Small Molecule PharmaceuticalNJ, NY, PA
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
543
By Phase
PHASE2/PHASE3: 1PHASE1/PHASE2: 1PHASE1: 1
By Status
RECRUITING: 2COMPLETED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07109414Lead Sponsor
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
PHASE2/PHASE3Recruiting
380 participants
Started: Aug 29, 2025 · Completed: Oct 24, 2029
NCT05023486Lead Sponsor
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
PHASE1/PHASE2Recruiting
140 participants
Started: Dec 7, 2021 · Completed: Mar 31, 2026
NCT03199586Lead Sponsor
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
PHASE1Completed
23 participants
Started: Dec 21, 2017 · Completed: May 7, 2020
Locations (1)
Headquarters
New York, NY, United States
Map
Loading map...